Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the ...
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple ...
The biggest change is a downgrade of ConocoPhillips, with BofA cutting COP to Underperform. Akamine cites the company’s “$53 breakeven and 4.4% free-cash-flow yield,” which the bank says “screen as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback